Catalent, Inc. to Present at the 29th Annual Piper Jaffray Healthcare Conference Tue, 14 Nov 2017 21:15:00 +0000 Catalent, Inc. , the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, today announced that Matthew Walsh, Executive Vice President & Chief Financial Officer, will present at the 29th Annual Piper Jaffray Healthcare Conference at 2:00 p.m.
ETFs with exposure to Catalent, Inc. : November 8, 2017 Wed, 08 Nov 2017 22:51:22 +0000 Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Catalent, Inc. Here are 5 ETFs with the largest exposure to CTLT-US. Comparing the performance and risk of Catalent, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more
(Read more...)
Catalent beats Street 1Q forecasts Mon, 06 Nov 2017 12:43:35 +0000 On a per-share basis, the Somerset, New Jersey-based company said it had net income of 3 cents. Earnings, adjusted for one-time gains and costs, were 21 cents per share. The results exceeded Wall Street ...
Catalent, Inc. Reports First Quarter Fiscal 2018 Results Mon, 06 Nov 2017 12:30:00 +0000 Catalent, Inc. , the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, today announced financial results for the first quarter of fiscal 2018, which ended September 30, 2017.
Catalent Completes Acquisition of Cook Pharmica Tue, 24 Oct 2017 06:00:00 +0000 Catalent, Inc. , the leading global provider of advanced delivery technologies and development solutions for drugs, biologics, and consumer health products, today announced it has completed the acquisition of Cook Pharmica LLC, an integrated provider of drug substance and drug product manufacturing and related services.
Catalent, Inc. Announces First Quarter Fiscal Year 2018 Earnings Conference Webcast Thu, 19 Oct 2017 20:32:00 +0000 Catalent, Inc. , the leading global provider of advanced delivery technologies and development solutions for drugs, biologics, and consumer health products, today announced that it will release financial results for the first quarter of fiscal year 2018 ended September 30, 2017, before the market open on Monday, November 6, 2017.
*Winners defined as our Top Picks that increased 20% or more within a 6-month period.
Red Letters imply that that particular criteria did not meet minimum requirements, e.g., a low GSA Rank would show it in red.
___ Red Line On Graph Shows a Trailing Stop Loss Based on Support and Resistance Levels. See how it works.
___ Blue Line On Graph Shows the 10-Week Moving Average.
___ Magenta Line On Graph Shows the 40-Week Moving Average.
Disclaimer The stock selections in our stock investing and stock trading database are not stock recommendations, but simply represent applications of a stock investing process. All materials, including our Top Stock Picks, are provided for information purposes only and should not be used or construed as an offer to sell, a solicitation of an offer to buy, or a recommendation for any security. Growth Stock Analytics, LLC is not responsible for gains/losses that may result in investing or trading in these securities. All information is believed to be obtained from reliable sources, but there is no guarantee that the information supplied is accurate, complete or timely. There is no guarantee or warranty with regard to the results obtained from its use. There is no guarantee of suitability or potential value of any particular investment or information source. You acknowledge that your requests for this information are unsolicited and shall neither constitute nor be considered investment advice. Past investing performance is not an indication of future performance results. Investing and trading in stocks is risky. Investors are encouraged to consult a registered stock broker or investment adviser before making any investing decisions. The interpretations and opinions expressed herein are solely those of Growth Stock Analytics, LLC, and not of any other individual or organization.